Moteur de recherche d’entreprises européennes
Financement de l’UE (3 970 006 €) : Identification et prise en charge des patients à risque – Résultats et événements vasculaires en dialyse péritonéale Hor 12/11/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Identification et prise en charge des patients à risque – Résultats et événements vasculaires en dialyse péritonéale
Peritoneal dialysis (PD) is an underused life saving renal replacement therapy for end-stage kidney disease. Nevertheless, PD patients remain at high risk for poor outcome, most notably excessive risk of cardiovascular disease. There is an unmet need for a risk-adjusted individualized PD approach. The IMPROVE-PD consortium provides 15 Early Stage Researchers (ESRs) in 11 partner institutes located in 7 different countries a state-of-the-art, multidisciplinary and intersectoral pan- European training programme including input from academic, clinical and industrial stakeholders. Network-wide and local training activities, individual research projects, intersectoral secondments and short laboratory visits will provide key generic skills and will prepare ESRs for future roles as highly skilled researchers in Europe. Well-phenotyped patient cohorts, and novel experimental models and techniques will be exploited by the ESRs, mentored by an excellent supervisory team, to improve future management of the PD patient at risk. This joint effort encourages productive collaboration between industrial and academic sectors though integrated projects and shared goals. Key findings will be communicated to a broad range of stakeholders through state of the art methods. IMPROVE-PD will give rise to a new generation of experts in PD with outstanding interdisciplinary research skills, intersectoral understanding and with perspective to pursue their careers in this scientific and industrial field. It will enable timely identification of the PD patient at high risk for adverse outcome, develop understanding of underlying pathomechanisms, and within an iterative process between research groups foster the development of innovative approaches to individualized treatment by targeting revealed pathomechanisms. Through these approaches, the ITN will achieve refinement of PD fluids, PD therapy and cardiovascular risk reduction.
| Australian and New Zealand Dialysis and Transplant (Anzdata) Registry | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 501 810 € |
| Baxter Medical Products GmbH | 264 207 € |
| Cardiff University | 606 345 € |
| Epsilon 3 GmbH | 0,00 € |
| Institut National de la Sante et de la Recherche Medicale | 274 802 € |
| Medizinische Universitaet Wien | 212 834 € |
| Stichting Amsterdam UMC | 265 620 € |
| Universidad Autonoma de Madrid | 250 905 € |
| Universitatsklinikum Heidelberg | 505 577 € |
| Universite Catholique de Louvain | 256 320 € |
| University of Keele Royal Charter | 303 173 € |
| Zytoprotec GmbH | 528 414 € |
https://cordis.europa.eu/project/id/812699
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australie.
